PsiOxus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PsiOxus Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10616
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PsiOxus Therapeutics Ltd (PsiOxus), formerly known as Myotec Therapeutics Ltd is a drug company that develops novel therapeutics for cancer and other clinically unmet diseases. The company provides pipeline product portfolio such as an oncolytic vaccine and a dual action anabolic catabolic transforming agent. It also has an antibody armed oncolytic platform under development. PsiOxus’s products find application in the treatment of various cancer diseases such as cachexia, sarcopenia, metastatic cancer and solid tumours, among others. The company holds expertise in enhancing the therapeutic potency, safety and delivery kinetics through genetic modification to produce cancer vaccines. PsiOxus is headquartered in Abingdon, the UK.

PsiOxus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 10
PsiOxus Therapeutics Raises Additional US$34 Million In Series B Financing 12
Partnerships 14
PsiOxus Therapeutics Enters into Collaboration Agreement with Parker Institute for Cancer Immunotherapy 14
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 15
Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 16
Licensing Agreements 17
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 17
Avidea Technologies Enters into Licensing Agreement with PsiOxus Therapeutics 18
PsiOxus Therapeutics Ltd – Key Competitors 19
PsiOxus Therapeutics Ltd – Key Employees 20
PsiOxus Therapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Jun 04, 2018: PsiOxus Therapeutics Names Melissa Epperly As Chief Financial Officer 22
Aug 17, 2017: PsiOxus Therapeutics Announce Two New Board Appointments: Strengthens US Presence 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PsiOxus Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 10
PsiOxus Therapeutics Raises Additional US$34 Million In Series B Financing 12
PsiOxus Therapeutics Enters into Collaboration Agreement with Parker Institute for Cancer Immunotherapy 14
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 15
Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 16
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 17
Avidea Technologies Enters into Licensing Agreement with PsiOxus Therapeutics 18
PsiOxus Therapeutics Ltd, Key Competitors 19
PsiOxus Therapeutics Ltd, Key Employees 20

List of Figures
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PsiOxus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PsiOxus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FTI Consulting, Inc.:企業の戦略・SWOT・財務情報
    FTI Consulting, Inc. - Strategy, SWOT and Corporate Finance Report Summary FTI Consulting, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Spire Inc (SR):企業の財務・戦略的SWOT分析
    Spire Inc (SR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Continental AG:企業のM&A・事業提携・投資動向
    Continental AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Continental AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Etablissementen Franz Colruyt NV (COLR):企業の財務・戦略的SWOT分析
    Etablissementen Franz Colruyt NV (COLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務分析
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CooperVision Inc-医療機器分野:企業M&A・提携分析
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …
  • Singapore Power Limited:企業の戦略・SWOT・財務情報
    Singapore Power Limited - Strategy, SWOT and Corporate Finance Report Summary Singapore Power Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819, a non-systemic yeast recombinant …
  • Greenphire Inc:医療機器:M&Aディール及び事業提携情報
    Summary Greenphire Inc (Greenphire) is a provider of clinical trial payment solutions that offers patients reimbursement and site payments. The company’s products portfolio includes ClinCard, ConneXTS and eClinicalGPS. Its eClinicalGPS is a global site that facilitates accurate payment calculation, …
  • Calpine Corporation:戦略・SWOT・企業財務分析
    Calpine Corporation - Strategy, SWOT and Corporate Finance Report Summary Calpine Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Stamps com Inc (STMP):企業の財務・戦略的SWOT分析
    Stamps com Inc (STMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BioMark Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • Kwality Group
    Kwality Group - Strategy, SWOT and Corporate Finance Report Summary Kwality Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Central Alabama Electric Cooperative Inc:企業の戦略的SWOT分析
    Central Alabama Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Pt Bakrieland Development Tbk
    Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • H&E Equipment Services Inc (HEES):企業の財務・戦略的SWOT分析
    Summary H&E Equipment Services Inc (H&E Equipment) is an integrated equipment company that provides rentals and sales services. The company rents, sells and provides parts and service support for new and used earthmoving equipments, material handling, forestry, concrete, industrial and heavy equipme …
  • Selcia Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Selcia Ltd (Selcia), formerly SCYNEXIS Europe Ltd is a contract research company that offers drug discovery services. The company operates through its divisions including selcia discovery - a drug discovery operation, incorporating proprietary fragment screening; and Selcia Radiolabeling - t …
  • Narada Power Source Co Ltd (300068):企業の財務・戦略的SWOT分析
    Summary Narada Power Source Co Ltd (Narada Power) is a battery manufacturer and distributor that markets and supplies stored energy solutions. The company's products include eos series batteries, acme series, acmeG series, GP series, TTG series, TT series, eosG series, GPG series, MP series, HRL ser …
  • Eaton Corporation Plc (ETN):電力:M&Aディール及び事業提携情報
    Summary Eaton Corporation Plc (Eaton) is a power management company. It designs, develops, and sells products and services, which help customers manage electrical, hydraulic and mechanical power more reliably, efficiently, safely, and sustainably. Eaton serves customers in the utility, governmental, …
  • Sandoz Inc:企業のM&A・事業提携・投資動向
    Sandoz Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sandoz Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆